Improved Outcomes & Reduced Readmissions Through AI-Driven Identification of High-Risk COPD Patients
Presentation
Time & Date: 2:30 – 3:55 PM CET, June 15th, 2026
Session: Accelerating AI Development in the UK
Location: Room G103
Learn how Pangaea’s guideline-configured AI platform is helping health systems globally to proactively identify COPD patients at high risk of exacerbation who are not receiving guideline-directed care, achieving 96% accuracy. Now deploying across health systems in 14 countries, the platform is also demonstrating 100% accuracy in identifying metastatic breast cancer patients requiring biomarker testing and high performance in detecting asthma patients at risk of exacerbation or death, helping healthcare systems move from reactive to proactive care.
By embedding continuously updated clinical guideline logic directly into real-world EHR data, Pangaea enables scalable, real-time patient identification and intervention across multiple diseases and geographies.
Demo Station
Location: UK Pavilion (F100-3)
See firsthand how Pangaea’s AI platform helps close care gaps by finding untreated and under-treated patients across prevalent and rare hard-to-diagnose conditions at the point of care and for population health. This is enabling timely, guideline-concordant screening and care, without requiring prompting or disrupting existing clinical workflows.
Please let us know if you are available to meet by registering through the form below or emailing us at info@pangaeadata.ai
Register to Meet Us
Attendees
